Abstract
Results Median age was 6 years (10 months to 17 years) when ISAC was first performed, and 8 years (22 months to 18 years) when the latest ISAC was performed. With respect to the number and intensity of IgE reactivities, ISAC follow-up results entered one of the following categories: progression (16), stability (12), attenuation (8). Two patients displayed complex alterations of their molecular profile over time. In most cases, ISAC followup provided aid for the management of food exclusion or reintroduction regimens. Storage protein reactivity was the most frequent setting, but transition from one molecular profile to another, which were not clinically distinguishable, such as lipid tranfer proteins versus thaumatin-like proteins, was als noted. Complex cross-reactivity patterns or allergy to components which are unavailable for individual testing (sesame Ses i 1, thaumatin-like Act d 2, 7S vicillins other than those from Fabaceae, wheat Tri a 14) gained better insight from repeated ISAC assays. Finally, sequential “allergen landscape views” improved the understanding of the patient’s biological and clinical evolution.
Highlights
Allergen microarray testing is increasingly used as a diagnostic tool for complex allergies, but its potential as a follow-up means has not been established yet
From 2010 through 2013, allergen microarray testing (ISAC®, ThermoFisher Phadia) was performed more than once in 38 pediatric patients according to their clinical status, skin prick testing and previous laboratory results
Allergy to components which are unavailable for individual testing gained better insight from repeated ISAC assays
Summary
Allergen microarray testing is increasingly used as a diagnostic tool for complex allergies, but its potential as a follow-up means has not been established yet. Sequential allergen microarray testing during the follow-up of allergic patients From 5th International Symposium on Molecular Allergology (ISMA 2013) Vienna, Austria.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
